CLASSIFICATIO MECHANISM OF CONTRAINDICATIO ADVERSE

DRUG DATA ACTION

INDICATIONS NURSING RESPONSIBILITIES
N N EFFECTS
Generic Name: Pharmacologic: Tranexamic acid General: > Hypersensitivity CNS: Dizziness Before:
Tranexamic Antifibrinolytic competitively inhibits > treatment of > Active Intravascular > check the doctor’s order
Acid activation of excessive Clotting EENT: Visual > Observe the 15 rights of drug
plasminogen (via bleeding resulting > Acquired defective abnormalities administration
Trade name/s: binding to the kringle from systemic or color vision > Do skin testing
Cyklokapron, domain), thereby local > Subarachnoid CV: Hypotension, > Tell patient to inform the healthcare
Hemostan, reducing conversion hyperfibrinolysis Hemorrhage thromboembolism, provider if color blind, have a history
Lysteda Therapeutic: of plasminogen to > prophylaxis in thrombosis of stroke, and blood clot, or bleeding
Hemostatic Agent plasmin (fibrinolysin), patients with in your brain.
Dose/Route/Freq: an enzyme that coagulopathy GI: Diarrhea, > Caution patient to avoid products
500mg IV q8h degrades fibrin clots, undergoing Precautions: nausea, vomiting containing aspirin or NSAIDs
fibrinogen, and other surgical Use cautiously with renal > For women who are taking to
plasma proteins, procedures impairment, hematuria control heavy bleeding, the
including the originating in the upper medication should only be taken
procoagulant factors urinary tract; and during the menstrual period
V and VIII conditions associated
with increased thrombus During:
formation > administer the drug at the right
A: 100% bioavailable dosage and route in the right time
with IV administration Patient’s actual > check the patency of the IV site
D: Penetrates readily indication: and IV line
into joint fluid and Treatment of Interactions: > Do not use this medication without
synovial membranes excessive > drug-drug: concurrent telling your doctor if you are
M and E: 95% bleeding resulting use of clotting factor breastfeeding a baby
excreted unchanged from systemic or complexes may ↑ the
in urine local risk of thrombotic After:
hyperfibrinolysis complications (give > Advise patient to take medication
Onset: Unknown tranexamic acid 8 hr exactly as directed
Peak: Unknown following clotting factor > Unusual change in bleeding pattern
Duration: 7-8hours replacement therapy) should be reported to the physician
Drug Half-Life: 6 > Report severe allergic reactions
hours such as rash, hives, itching, dyspnea,
tightness in the chest, swelling of the
mouth, face, lips or tongue
> If the patient missed a dose, let
patient take when remembered, then
take next dose at least 6 hours later.
> Store this medication at room
temperature away from moisture and
heat